AI Summary
We reviewed 4 live results for hadlima and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Pharmaceutical and Specialty Medicine.
Comparison Table
Recommended
Hadlima (adalimumab-bwwd)
Source: Organon (Thailand) Ltd.
Description
In Thailand, Hadlima is categorized as a Special Control drug used to manage severe autoimmune and inflammatory diseases such as Ankylosing Spondylitis and Rheumatoid Arthritis. It is primarily available through hospital-based prescriptions under medical supervision, ensuring patients receive high-quality specialty biologic care for their conditions.
Best for
hospital-based prescriptions, Thai autoimmune treatment, Special Control medication access and supervised biologic administration
View Details
Rating
Hadlima
Source: Samsung Bioepis / Organon
Description
Hadlima is an adalimumab biosimilar widely used for inflammatory diseases. While not a primary registered brand for commercial supply in Singapore, it has significant availability and approval in the United States, Australia, and Canada.
Best for
US healthcare market, Australian pharmaceutical access and Canadian healthcare patients
View Details
Rating
HADLIMA (adalimumab-bwwd)
Source: Organon & Co.
Description
HADLIMA is an FDA-approved interchangeable biosimilar to Humira, acting as a tumor necrosis factor (TNF) blocker. It is indicated for treating chronic conditions such as rheumatoid arthritis, Crohn’s disease, and plaque psoriasis. The medication is offered in citrate-free formulations in both high-concentration (40 mg/0.4 mL) and low-concentration (40 mg/0.8 mL) options. Delivery formats include the PushTouch single-dose autoinjector and prefilled glass syringes, accompanied by the HADLIMA For You patient support program for injection training and co-pay assistance.
Best for
patients seeking Humira alternatives, citrate-free injection preference, rheumatoid arthritis management, Crohn’s disease treatment and convenient self-administration
View Details
Rating
| Compare | Hadlima (adalimumab-bwwd) | Hadlima | HADLIMA (adalimumab-bwwd) |
|---|---|---|---|
| Source | Organon (Thailand) Ltd. | Samsung Bioepis / Organon | Organon & Co. |
| Description | In Thailand, Hadlima is categorized as a Special Control drug used to manage severe autoimmune and inflammatory diseases such as Ankylosing Spondylitis and Rheumatoid Arthritis. It is primarily available through hospital-based prescriptions under medical supervision, ensuring patients receive high-quality specialty biologic care for their conditions. | Hadlima is an adalimumab biosimilar widely used for inflammatory diseases. While not a primary registered brand for commercial supply in Singapore, it has significant availability and approval in the United States, Australia, and Canada. | HADLIMA is an FDA-approved interchangeable biosimilar to Humira, acting as a tumor necrosis factor (TNF) blocker. It is indicated for treating chronic conditions such as rheumatoid arthritis, Crohn’s disease, and plaque psoriasis. The medication is offered in citrate-free formulations in both high-concentration (40 mg/0.4 mL) and low-concentration (40 mg/0.8 mL) options. Delivery formats include the PushTouch single-dose autoinjector and prefilled glass syringes, accompanied by the HADLIMA For You patient support program for injection training and co-pay assistance. |
| Best for | hospital-based prescriptions, Thai autoimmune treatment, Special Control medication access and supervised biologic administration | US healthcare market, Australian pharmaceutical access and Canadian healthcare patients | patients seeking Humira alternatives, citrate-free injection preference, rheumatoid arthritis management, Crohn’s disease treatment and convenient self-administration |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Hadlima (adalimumab-bwwd) from Organon (Thailand) Ltd.."
I picked this because Offers essential specialty access to adalimumab biosimilar therapy for Thai patients through established hospital distribution and professional medical oversight.
Share this search
Related Finds